+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact userservices@mhprofessional.com.
++
Content Update
May 06, 2024
Risperidone Extended-Release Injectable Suspension (Uzedy): A New Second-Generation Long-Acting Antipsychotic Formulation of Risperidone Approved for Treatment of Schizophrenia: Uzedy is a long-acting injectable antipsychotic that merges risperidone with an advanced drug delivery system, which has demonstrated effectiveness in treating schizophrenia. Two phase three trials, RISE and SHINE, showcased its efficacy and safety. RISE, a randomized, double-blind study involving 544 patients, revealed Uzedy significantly extends the time to relapse by 5 times and 2.7 times with once-monthly and once-every-2-months dosing, respectively, compared to placebo. SHINE, a parallel-group study with 336 patients, highlighted the favorable safety profile of Uzedy over 56 weeks. Uzedy’s unique attribute lies in its prolonged dosing interval, spanning up to 2 months, setting it apart from other risperidone formulations. However, more comparative trials with active treatments are warranted to fully understand its positioning among second-generation long-acting injectable antipsychotics.
++
Content Update
December 12, 2023
Abilify Asimtufii®: A Newly Approved Bimonthly Long Acting Injectable: A new dosage form of aripiprazole monohydrate (Abilify Asimtufii®), was approved by the U.S. Food and Drug Administration (FDA) in April 2023 for schizophrenia and maintenance monotherapy treatment of bipolar I disorder. It is a 960 mg long-acting injectable administered into the gluteal muscle every 2 months, in contrast to Abilify Maintena®, which is administered monthly into the deltoid or gluteal muscle. In a 32-week open-label trial, Abilify Asimtufii® showed comparable aripiprazole plasma concentrations (geometric means ratio 1.011) and treatment-emergent adverse events (71.2% vs. 70.9%) to Abilify Maintena®. This newly approved formulation represents a step forward in offering patients more convenient and tolerable treatment options, enhancing adherence rates, and improving quality of life for individuals suffering from severe psychiatric disorders.
++
Content Update
May 09, 2022
Lybalvi® Use in Patients with Bipolar I Disorder and Schizophrenia: Lybalvi® is a combination drug that contains olanzapine, a second-generation antipsychotic, and samidorphan, an opioid antagonist. It was U.S Food and Drug Administration approved in 2021 for the treatment of schizophrenia and for symptoms of psychosis associated with bipolar I disorder. Use of Lybalvi ® aims to increase medication adherence, treat and prevent metabolic comorbid conditions, and improve patient quality of life.
++
LEARNING OBJECTIVES
Upon completion of the chapter, the reader will be able to:
Recognize signs and symptoms of schizophrenia and be able to distinguish among positive, negative, and cognitive impairments associated with the illness.
Explain potential pathophysiologic mechanisms that are thought to underlie schizophrenia.
Identify treatment goals for a patient with schizophrenia.
Recommend appropriate antipsychotic medications based on patient-specific data.
Compare side effect profiles of individual antipsychotics.
Educate patients and families about schizophrenia, treatments, and the importance of adherence to antipsychotic treatment.
Describe components of a monitoring plan to assess the effectiveness and safety of antipsychotic medications.
++...